Royal Bank Of Canada set a $6.00 target price on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) in a report released on Friday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, August 9th. Zacks Investment Research cut shares of AcelRx Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, July 11th. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, August 4th. Piper Jaffray Companies set a $3.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a hold rating in a research note on Tuesday, July 25th. Finally, Jefferies Group LLC reiterated a buy rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $7.50.

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 2.95 on Friday. The stock has a 50 day moving average price of $2.99 and a 200 day moving average price of $2.80. AcelRx Pharmaceuticals has a 1-year low of $1.95 and a 1-year high of $4.08. The stock’s market capitalization is $133.87 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. The firm had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. Equities research analysts anticipate that AcelRx Pharmaceuticals will post ($1.13) EPS for the current year.

WARNING: “Royal Bank Of Canada Reiterates “$6.00” Price Target for AcelRx Pharmaceuticals, Inc. (ACRX)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2017/08/28/royal-bank-of-canada-reiterates-6-00-price-target-for-acelrx-pharmaceuticals-inc-acrx.html.

In related news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $2.40, for a total value of $2,100,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pamela P. Palmer acquired 10,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average price of $2.95 per share, with a total value of $29,500.00. The disclosure for this purchase can be found here. Insiders purchased 30,000 shares of company stock valued at $89,600 in the last quarter. Company insiders own 28.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. ING Groep NV boosted its stake in shares of AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 26,000 shares during the period. Acadian Asset Management LLC boosted its stake in shares of AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 32,087 shares during the period. Teachers Advisors LLC boosted its stake in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 8,475 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the period. Finally, Virtu KCG Holdings LLC boosted its stake in shares of AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Hedge funds and other institutional investors own 23.32% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.